World's First Collagen for Neck Wrinkle Filling Approved, Recombinant Collagen Enters a New Era of Injection
In early July 2026, Giant Biogene's cross-linked recombinant collagen implant officially obtained a Class III medical device registration certificate, becoming the world's first recombinant collagen product for neck wrinkle filling. This milestone event marks the further expansion of recombinant collagen application scenarios from traditional facial anti-aging to refined neck management, and also injects new growth momentum into the entire recombinant collagen industry chain.
Shortly after, Jinbo Bio's Viianmi recombinant type III humanized collagen freeze-dried fiber successfully renewed its certificate, with the new registration certificate valid until June 2031. The indication for this product is facial dermal tissue filling to correct dynamic forehead wrinkles, and it is one of the benchmark products in China's recombinant collagen injection field.
Judging from the density of product approvals, the activity level of the recombinant collagen track in the first half of 2026 reached an unprecedented level. Whether as injectable fillers or wound repair materials, recombinant collagen is becoming the most closely watched bioactive ingredient in medical aesthetics and functional skincare.
Why Is Recombinant Collagen So Popular?
The core advantage of recombinant collagen lies in its high homology with human collagen. Recombinant collagen expressed through genetic engineering technology is highly consistent with the human body's own collagen in terms of amino acid sequence, triple helix structure, and biological activity, which makes it significantly superior to animal-derived collagen in immunogenicity and biocompatibility.
In the field of medical aesthetics injections, recombinant collagen as a filling material has several unique advantages: first, good biodegradability, with metabolic products being amino acids and water, ensuring high safety; second, certain biological stimulation activity that can promote autologous collagen regeneration; third, allergic reaction risk far lower than animal-derived collagen, with no preoperative skin test required.
In the field of wound repair, the application of recombinant collagen is more mature. As Class II medical devices, recombinant collagen dressings, gels, sprays, and other products have been widely used in post-medical-aesthetics repair, chronic wound care, burn and scald treatment, and other scenarios. Their mechanisms of promoting cell migration, accelerating epithelialization, and reducing scar formation have been supported by a large amount of clinical literature.
From Injection to Skincare: Full-Scenario Coverage of Recombinant Collagen
At present, the application of recombinant collagen has covered a complete product spectrum from Class III injectable devices to Class II repair dressings:
Class III medical devices (injectables): Including facial fillers, neck wrinkle fillers, collagen for water-light injection, etc., requiring strict clinical trials and NMPA review, with high technical barriers and relatively high market value.
Class II medical devices (repair): Including recombinant collagen repair dressings, repair gels, sprays, freeze-dried fibers, etc. Such products do not require clinical trials (as long as they comply with the clinical exemption catalog), but still require strict biosafety evaluation and system assessment, and are the category with larger shipment volumes for OEM companies.
Cosmetic-grade skincare (daily use): Recombinant collagen is added as a functional ingredient in essences, creams, masks, and other skincare products, achieving long-term collagen supplementation and anti-aging maintenance through daily skincare.
Weitai Group has product layouts at all three levels. At the Class II device level, it already has medical recombinant collagen repair dressings, medical recombinant collagen gels, recombinant collagen freeze-dried fibers, and other Xiangxiang Medical Device Registration products, covering three major forms: dressings, gels, and water-light products.
Technology Iteration Direction: From Single Collagen to Composite Formulas
The industry's cutting-edge trend is developing from single recombinant collagen toward composite formulas. Composite freeze-dried fibers of collagen + hyaluronic acid, synergistic repair systems of recombinant collagen + peptides, and healing-promoting combinations of collagen + mussel adhesive protein are all key directions of current R&D investment.
This compounding trend places higher demands on the formula R&D capabilities of OEM companies. It is not simply mixing several raw materials together, but requires consideration of the compatibility of active ingredients, formulation stability, synergistic mechanisms, and final clinical efficacy verification.
Production Capacity and Supply Chain: Key Factors Determining Competitiveness
With the explosive growth of market demand for recombinant collagen, production capacity has become an important factor constraining enterprise development. Companies with independent fermentation platforms, purification processes, and freeze-drying capacity have obvious advantages in cost control and delivery cycles.
Taking Weitai Group as an example, its four smart factories are equipped with 15 intelligent freeze-drying equipment, with daily output of 1 million pairs of freeze-dried powder and annual output exceeding 300 million pairs. Combined with Class 100,000/Class 10,000 cleanrooms and Class 100 freeze-drying environments, it can meet the order needs of large-scale brand customers. This large-scale production capacity will become a key competitiveness for undertaking orders when industry demand is concentratedly released.
Compliance Red Lines Cannot Be Crossed
While recombinant collagen products are developing rapidly, compliance requirements are also continuously tightening. The classification adjustment announcement and dynamic adjustment procedures released in June 2026 put forward clearer requirements for the classification definition of recombinant collagen products. Recombinant collagen for injection belongs to Class III devices, while repair dressings belong to Class II devices, and the two cannot be confused.
At the same time, product claims must also strictly comply with regulations. Efficacy claims for recombinant collagen products need to be supported by sufficient scientific evidence and cannot be arbitrarily exaggerated. As manufacturing enterprises, every link from raw material selection, formula design, registration application to production quality control needs to be compliant and traceable.
Outlook
The recombinant collagen track is at a turning point from technological breakthroughs to large-scale application. Product approvals in the injection field are accelerating, market demand in the repair field continues to be strong, and consumer awareness in the skincare field is rapidly increasing. For enterprises that have been in this field for many years, the window period of the next three years is crucial.
The moat of technology, the moat of production capacity, and the moat of compliance—only the superposition of all three can form a true competitive barrier. In this recombinant collagen competition, the ultimate winners will definitely be those enterprises that understand technology, production, and compliance.
Data sources for this article: National Medical Products Administration registration information, Jinfeiying Pharmaceutical and Medical Device Registration Service Industry Briefing (July 2026), corporate public information
About Weitai Group | OEM/ODM Contract Manufacturing Services
Weitai Group was founded in 2012 and has been engaged in medical aesthetics functional skincare for 25 years. It is an OEM/ODM contract manufacturer with many years of experience in the medical aesthetics skincare industry. Its four factories (Guangzhou, Hunan, Zhaoqing) cover a total area of over 150,000 m², with 50+ fully automatic production lines, holding more than 110 Class II medical device registrations and filings, and accumulating a mature formula library + mature formulas and 72 patents.
Core contract manufacturing capabilities:
- Medical dressings/masks (daily output of 1 million pieces, Class II medical device certificate)
- Freeze-dried powder (daily output of 1 million pairs, developed by its own R&D laboratory)
- Essence serums/lotions and creams (full category of cosmetic-grade products)
- Medical gels/hemostatic materials (Class II medical device certificate)
Quality assurance: Dual certification of US GMPC + EU ISO22716, 38 quality inspections, yield rate 99.99%. Has served hundreds of brands (including Chando, etc.).
Cooperation models: OEM processing with supplied materials | ODM private-label customization | Shitaqi spot supply
Delivery capability: Regular 7-15 days, expedited shipment in 3 days. Official website: www.weitaigd.com